119
Identification of Infectious Agents in Pediatric Bronchoalveolar Lavage Specimens Using Standard versus Molecular Diagnostic Methods

Methods: We performed a pilot study to evaluate different diagnostic strategies for BAL specimens. We compared standard culture-based methods, commercially available molecular methods for respiratory viruses (FilmArray, Biofire, Inc.) and herpes viruses, and the investigational methods 16S ribosomal Sanger and Illumina sequencing which amplify DNA to identify bacteria from variable regions of the 16S ribosomal subunit gene. Eligible subjects were ≤18 years of age and underwent BAL from May 2013 to February 2014 for potential infection or structural anomalies. Mixed commensal flora (MCF) was not considered pathogenic.
Results: Thirty-three subjects underwent BAL; 9 had cystic fibrosis (CF); 4 had oncologic disease; 4 had laryngotracheomalacia; 2 had heart transplants; 2 had asthma; 8 had other conditions, e.g., foreign body, plastic bronchitis and interstitial lung disease; and 4 had chronic respiratory symptoms, but no identified diagnosis. Overall, 30/33 (91%) subjects had positive BALs for 51 potential pathogens (30 bacteria, 14 viruses, 7 fungi). Concordant results were noted for 4/4 subjects with nasopharyngeal swab sent for RT-PCR within 3 days of BAL. 16S Sanger sequencing was 75% (6/8) concordant with bacterial cultures, and deeper Illumina sequencing was 67% (16/24) concordant. Both methods detected potential pathogens in 2 other BAL. The yield of standard versus molecular methods is shown (Table).
Conclusion: Most subjects had a pathogen detected by available techniques. However, 16S sequencing identified potential pathogens not identified by standard methods. Future studies should assess the utility of the relative organism burden derived from 16S sequencing as well as amplified DNA for fungal and mycobacterial pathogens.
Positive BAL Specimens: Standard versus Molecular Methods |
||||
Pathogen1 |
Culture-based |
Molecular - Viruses |
16S |
Illumina |
Bacteria |
23 |
NA |
8 |
18 |
MCF |
6 |
NA |
NA |
NA |
Virus |
NA |
13 |
NA |
NA |
Fungal |
7 |
NA |
NA |
NA |
Overall |
27/33 (82%) |
13/25 (52%) |
8/25 (32%) |
18/24 (75%) |
111 subjects had co-infections.

S. Nadimpalli,
None
S. Hannah, None
C. Gina, None
T. Hammer, None
H. Jessica, None
A. Constantinescu, None
P. Satwani, None
F. Noah, None
L. Saiman, Cystic Fibrosis Foundation: Collaborator, Consultant and Scientific Advisor, Consulting fee and Salary
M. Foca, None
See more of: Oral Abstract Session